In vivo, SDF-1α mRNA promoted angiogenesis in a Matrigel plug model and significantly improved blood flow recovery, vascular density, and functional outcomes in ischemic limbs, highlighting its potential as a novel therapeutic approach for PAD and broader ischemic diseases. This evidence concerns the gene CXCL12 and peripheral arterial disease.